These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19499193)

  • 1. [Anticoagulation with warfarin].
    Schinzel H; Nitschmann S
    Internist (Berl); 2009 Aug; 50(8):1026-8. PubMed ID: 19499193
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacogenetic-based dosing of warfarin.
    Med Lett Drugs Ther; 2008 May; 50(1286):39-40. PubMed ID: 18487958
    [No Abstract]   [Full Text] [Related]  

  • 4. Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?
    Biss TT; Kamali F
    Pharmacogenomics; 2012 Aug; 13(11):1211-4. PubMed ID: 22920389
    [No Abstract]   [Full Text] [Related]  

  • 5. Estimation of the warfarin dose with clinical and pharmacogenetic data.
    ; Klein TE; Altman RB; Eriksson N; Gage BF; Kimmel SE; Lee MT; Limdi NA; Page D; Roden DM; Wagner MJ; Caldwell MD; Johnson JA
    N Engl J Med; 2009 Feb; 360(8):753-64. PubMed ID: 19228618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic pharmacogenetic models in anticoagulation therapy.
    Bon Homme M; Reynolds KK; Valdes R; Linder MW
    Clin Lab Med; 2008 Dec; 28(4):539-52. PubMed ID: 19059061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets.
    Le Cam-Duchez V; Frétigny M; Cailleux N; Gandelin C; Lévesque H; Borg JY
    Thromb Res; 2010 Sep; 126(3):e235-7. PubMed ID: 20569971
    [No Abstract]   [Full Text] [Related]  

  • 9. Pathology consultation on warfarin pharmacogenetic testing.
    Stack G;
    Am J Clin Pathol; 2011 Jan; 135(1):13-9. PubMed ID: 21173120
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
    Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F
    Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is a "pharmacogenomic algorithm" helpful for adjusting the initial dose of warfarin in patients to be treated by warfarin therapy?
    Goto S
    Circ J; 2010 May; 74(5):850-1. PubMed ID: 20424335
    [No Abstract]   [Full Text] [Related]  

  • 13. Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
    Fukuda T; Tanabe T; Ohno M; Tougou K; Fujio Y; Azuma J; Yamamoto I; Takeda A
    Clin Pharmacol Ther; 2006 Nov; 80(5):553-4. PubMed ID: 17112813
    [No Abstract]   [Full Text] [Related]  

  • 14. Warfarin pharmacogenetics: ready for clinical utility?
    Baudhuin LM
    Clin Lab Sci; 2009; 22(3):151-5. PubMed ID: 19827409
    [No Abstract]   [Full Text] [Related]  

  • 15. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study.
    van Schie RM; el Khedr N; Verhoef TI; Teichert M; Stricker BH; Hofman A; Buhre PN; Wessels JA; Schalekamp T; le Cessie S; van der Meer FJ; Rosendaal FR; de Boer A; Maitland-van der Zee AH; Visser LE
    Pharmacogenomics; 2012 Aug; 13(11):1239-45. PubMed ID: 22920394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.
    Shaw PB; Donovan JL; Tran MT; Lemon SC; Burgwinkle P; Gore J
    J Thromb Thrombolysis; 2010 Aug; 30(2):220-5. PubMed ID: 20204461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
    Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin monitoring woes: a glimmer of hope with pharmacogenomics.
    Beier MT
    J Am Med Dir Assoc; 2008 Mar; 9(3):199-200. PubMed ID: 18294604
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimization of warfarin dose by population-specific pharmacogenomic algorithm.
    Pavani A; Naushad SM; Rupasree Y; Kumar TR; Malempati AR; Pinjala RK; Mishra RC; Kutala VK
    Pharmacogenomics J; 2012 Aug; 12(4):306-11. PubMed ID: 21358752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.